Stockscreener 앱 받기
7.18
0.14%
0.010
전일 마감가:
$7.17
열려 있는:
$7.17
하루 거래량:
6.96M
Relative Volume:
0.67
시가총액:
$2.66B
수익:
$3.49M
순이익/손실:
$-663.48M
주가수익비율:
-3.2072
EPS:
-2.2387
순현금흐름:
$-115.08M
1주 성능:
-0.55%
1개월 성능:
+72.18%
6개월 성능:
+73.01%
1년 성능:
+91.98%
1일 변동 폭
$7.1607
$7.19
1주일 범위
$7.10
$7.21
52주 변동 폭
$3.06
$7.22
Ataibeckley Inc Stock (ATAI) Company Profile
명칭
Ataibeckley Inc
전화
1 929 207 2670
주소
C/O ATAI LIFE SCIENCES US, INC., NEW YORK
Compare ATAI vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATAI
Ataibeckley Inc
|
7.18 | 2.66B | 3.49M | -663.48M | -115.08M | -2.2387 |
VRTX
Vertex Pharmaceuticals Inc
|
477.36 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
656.01 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
918.22 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.23 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
271.77 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Ataibeckley Inc Stock (ATAI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-27 | 개시 | Deutsche Bank | Buy |
| 2026-01-20 | 개시 | Guggenheim | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-07-29 | 개시 | Oppenheimer | Outperform |
| 2024-11-18 | 재확인 | H.C. Wainwright | Buy |
| 2024-04-03 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-11-01 | 개시 | Loop Capital | Buy |
| 2021-11-30 | 개시 | Maxim Group | Buy |
| 2021-11-11 | 개시 | ROTH Capital | Buy |
| 2021-10-18 | 개시 | H.C. Wainwright | Buy |
| 2021-09-01 | 개시 | Jefferies | Buy |
| 2021-07-13 | 개시 | Berenberg | Buy |
| 2021-07-13 | 개시 | Canaccord Genuity | Buy |
| 2021-07-13 | 개시 | Cantor Fitzgerald | Buy |
| 2021-07-13 | 개시 | Citigroup | Buy |
| 2021-07-13 | 개시 | Cowen | Outperform |
| 2021-07-13 | 개시 | Credit Suisse | Outperform |
| 2021-07-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 개시 | Aegis Capital | Buy |
모두보기
Ataibeckley Inc 주식(ATAI)의 최신 뉴스
AtaiBeckley Inc. Revenue Breakdown – MUN:B72 - TradingView
AtaiBeckley Inc. Revenue Breakdown – FWB:B72 - TradingView
ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly - Stocktwits
AtaiBeckley Inc. Revenue Breakdown – LS:A41WEP - TradingView
Is AtaiBeckley (ATAI) A Bargain On Eli Lilly’s Takeover Deal? - simplywall.st
AtaiBeckley Inc. (ATAI) stock price, news, quote and history - Yahoo Finance UK
Why Is ATAI Stock Soaring 59% After-Hours? - Stocktwits
Form DEF 14A ATAI Beckley Inc For: 23 July By Investing.com - Investing.com Canada
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33% - Yahoo Finance
Key facts: Zepbound tops Wegovy; Novo sues; Lilly buys AtaiBeckley - TradingView
Lilly-AtaiBeckley Deal A Stamp Of Approval For Psychedelics - Law360
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders? - TradingView
H.C. Wainwright downgrades AtaiBeckley stock rating on Lilly deal By Investing.com - Investing.com India
H.C. Wainwright downgrades AtaiBeckley stock rating on Lilly deal - Investing.com UK
Tracking Cathie Wood: Backing Prime Medicine and SpaceX, Sells Off AtaiBeckley, Shopify - Moomoo
Eli Lilly Acquires AtaiBeckley to Expand Mental Health Treatment Pipeline in $3.8 Billion Deal - Global Legal Chronicle
AtaiBeckley (NASDAQ:ATAI) shares reflect 18% implied value for acquisition milestone entitlements - TechStock²
ATAIBECKLEY INC : BERENBERG CUTS TO HOLD FROM BUY; CUTS TARGET PRICE TO $7.45 FROM $14 - Bitget
AtaiBeckley (ATAI) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary - Quartr
ATAIBECKLEY INC : TD COWEN CUTS TO HOLD FROM BUY - Bitget
H.C. Wainwright Downgrades AtaiBeckley(ATAI.US) to Hold Rating, Cuts Target Price to $7.5 - Moomoo
J&J, AbbVie said to have also looked at AtaiBeckley before Lilly’s $2.8B deal - Endpoints News
ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside - TradingView
Berenberg Downgrades AtaiBeckley to Hold From Buy, Adjusts Price Target to $7.45 From $14 - Moomoo
TD Cowen Downgrades AtaiBeckley to Hold From Buy - marketscreener.com
Lilly Joins Psychedelic Drug Race With AtaiBeckley Buyout – Merger Arbitrage Mondays (NASDAQ:ATAI) - Seeking Alpha
Weekly Recap: Eli Lilly acquisition of AtaiBeckley and BPL-003 Phase 3 - TradingView
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders - TradingView
Why Did ATAI, PANW, TRV Stocks Surge To 52-Week Highs Last Week? - Yahoo Finance
AtaiBeckley (NASDAQ:ATAI) shares trade with Merger CVR valued near 19% of face - TechStock²
Why Did AAPL, ATAI, UNH Stocks Jump To 52-Week Highs Today? - Stocktwits
Eli Lilly (LLY) to Acquire AtaiBeckley for $2.8B - GuruFocus
Berenberg Bank Sticks to Their Buy Rating for Atai Beckley N.V. (ATAI) - The Globe and Mail
Maxim Group Maintains AtaiBeckley(ATAI.US) With Hold Rating - Moomoo
Eli Lilly psikedelik ilaç üreticisi AtaiBeckley’yi 2,8 milyar dolara satın alıyor; zihinsel hastalık tedavilerinde yeni seçeneklerin devreye girmesi bu satın almanın gündeme gelmesinde önemli bir etken. Bu satın almayla Lilly, AtaiBeckley’nin deneysel DMT bazlı ila - instagram.com
TD Cowen Downgrades AtaiBeckley(ATAI.US) to Hold Rating - Moomoo
Form 13D/A AtaiBeckley Inc. For: 17 July By Investing.com - Investing.com Canada
AtaiBeckley Inc. (NASDAQ: ATAI) investor commits 15.4% stake to Lilly deal - Stock Titan
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc.ATAI - Business Wire
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu’s Fashion - Benzinga
A Quick Look at Today's Ratings for AtaiBeckley(ATAI.US), With a Forecast Between $7.5 to $8 - Moomoo
Eli Lilly Expands with $2.8B Psychedelic Acquisition - Investing News Network
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout - TradingView
Eli Lilly Drops $3.8 Billion on AtaiBeckley, Sending Psychedelic Stocks Soaring - finance.biggo.com
This ONEOK Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Eli Lilly agrees to $3.8B psychedelic buy - Axios
Biotech Growth says Eli Lilly's $2.8bn swoop on AtaiBeckley underlines the value of smaller drug developers - QuotedData
Lilly to buy AtaiBeckley in $3.8B psychedelic push - MSN
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - TradingView
AtaiBeckley acquisition highlights growing Big Pharma interest in psychedelics, says Jefferies - Proactive financial news
AtaiBeckley (NASDAQ:ATAI) shares reflect merger rights valued at 14% of par - TechStock²
Ataibeckley Inc (ATAI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Ataibeckley Inc 주식 (ATAI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HERSHBERG ROBERT | Director |
Jul 07 '26 |
Sale |
4.96 |
100,000 |
496,000 |
100,000 |
0.46%
0.84%
자본화:
|
볼륨(24시간):